Nitrofurantoin
NDC Package 16571-740-24

11-digit billing NDC: 16571074024 · Billing unit: ML · 230 ML per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Nitrofurantoin is oral suspension is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli, Enterococcus species, Staphylococcus aureus, Klebsiella species and Enterobacter species.Limitations of UseNitrofurantoin oral suspension is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)].UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin oral suspension and other antibacterial drugs, nitrofurantoin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Marketed by Rising Pharma Holdings, Inc., this product is identified by NDC 16571-740 and is authorized under FDA application NDA009175.

Identification & Billing

NDC Package Code
16571-740-24
Package Description
1 BOTTLE in 1 CARTON / 230 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
16571074024
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
230 ML
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Nitrofurantoin
Dosage Form
-
Usage Information
Nitrofurantoin oral suspension is indicated in adults and pediatric patients 1 month of age and older for the treatment of urinary tract infections due to susceptible strains of Escherichia coli, Enterococcus species, Staphylococcus aureus, Klebsiella species and Enterobacter species.Limitations of UseNitrofurantoin oral suspension is not indicated for the treatment of pyelonephritis or perinephric abscesses [see Warnings and Precautions (5.7)].UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin oral suspension and other antibacterial drugs, nitrofurantoin oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Rising Pharma Holdings, Inc.
FDA Application #
NDA009175
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
12-23-2020
End Marketing Date
05-01-2025
Listing Expiration
05-01-2025
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16571-740-24 identifies a specific commercial package of 1 bottle in 1 carton / 230 ml in 1 bottle of Nitrofurantoin, labeled by Rising Pharma Holdings, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Rising Pharma Holdings, Inc. on December 23, 2020. The current certification is valid through May 01, 2025.

How is this Rising Pharma Holdings, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16571074024. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 230 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16571-740-24
11-Digit CMS (5-4-2)
16571-0740-24

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.